Elicio Therapeutics Inc (ELTX) Stock Price, Quote & News

Company Profile

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph nodetargeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph nodetargeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 209 0050

Website: elicio.com

Address:

451 D Street, 5th Floor Suite 501, Boston, United States

Woooehoo Nov. 14 at 5:00 PM

$ELTX moving to H1, pending they weren’t slow to enroll (I have no insight to think they would have been based on patient population). I think this is more bullish on a probability basis than previously. Especially considering the independent monitoring committee told them to keep going in June with no changes. Runway doesn’t matter really anymore as GKCC seems to be funding the company through each milestone. Data should be interesting…if they prove efficacy, this is pretty ground breaking for cancer vaccines generally. All the while Rev Med continues to trend higher on the hopes of being the market leader in KRAS. Good data here would beg to question that entire valuation.

0 · Reply

GA09 Nov. 14 at 1:05 PM

$ELTX Another delay in release of the data. It was supposed to be Q1 2025, then Q3 2025, then Q4 2025 and now 1st half of 2026. They keep changing the goal posts. Does this make sense?

1 · Reply

justiceforb_85 Nov. 14 at 3:35 AM

$ELTX think it's likely good news of delay of DFS to H1 '26. Science behind ELI-002 7P is strong. Financials of company are a bit shaky. Would be nice to see a possible buyout before data read-out.

2 · Reply

GA09 Nov. 11 at 7:45 PM

$ELTX If data is strong or much better than prior data, this one rallies significantly and gets acquired sooner rather than later. It is a $10 billion opportunity or more with it being able to treat other KRAS mutant cancers. Potential bidders could be MRK, BMY, or GILD for anywhere between $5B - $10B.

1 · Reply

DARKP00L Nov. 7 at 2:24 PM

$ELTX 09:10 on Nov. 07 2025 Elicio Announces Additional Immunogenicity Data From Ongoing Phase 2 AMPLIFY-7P Trial Evaluating ELI-002 7P In Patients With mKRAS PDAC And New Preclinical Data On Immunotherapy Candidate ELI-004, For Treatment Of Solid Tumors #tradeideas

0 · Reply

Woooehoo Nov. 6 at 3:00 PM

$ELTX I am suspecting a rise to 12-16 on good data and 30+ if transformational. Mixed data or bad this is going down to 3-4 again or lower. Based on existing data and high level signs of efficacy from the phase 1. I would suspect good data is likely which takes us to 12-16 initially and then we probably trade back down to 8-10 with financing overhang looming. For us to sustain a large stock price increase we need big institutional buy in or a partner which could come following the phase 2 if good or great. Only other thing would be data so good that fda doesn’t need a phase 3, which is that unlikely transformational scenario. Good luck all!

1 · Reply

Cbra Nov. 4 at 12:04 PM

$ELTX agreed, it’s as if nobody knows what’s going with this company, in this sector!

2 · Reply

humdime Nov. 4 at 11:10 AM

$ELTX With ELI-004 in the mix, the company’s appeal and valuation increase in the event of a potential sale — assuming the clinical results are as promising as they seem. Too bad the market doesn’t appreciate it for now.

0 · Reply

Olatz Nov. 3 at 4:28 PM

$ELTX https://elicio.com/press_releases/elicio-therapeutics-to-present-clinical-and-preclinical-data-at-the-sitc-2025-annual-meeting/

0 · Reply

justiceforb_85 Oct. 27 at 7:43 PM

$ELTX excellent data update. Look forward to DFS data.

1 · Reply

Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Nov 7, 2025, 4:06 PM EST - 9 days ago

Elicio Therapeutics: Running On Fumes, But A Definitive Readout Appears Imminent

Nov 7, 2025, 9:00 AM EST - 9 days ago

Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC

Nov 3, 2025, 8:00 AM EST - 13 days ago

Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting

Oct 27, 2025, 8:00 AM EDT - 20 days ago

Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial

Sep 29, 2025, 8:00 AM EDT - 6 weeks ago

Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma

Sep 18, 2025, 8:00 AM EDT - 2 months ago

Elicio Therapeutics Reports Inducement Grants

Sep 17, 2025, 8:00 AM EDT - 2 months ago

Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial

Aug 12, 2025, 8:00 AM EDT - 3 months ago

Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients

Aug 7, 2025, 4:30 PM EDT - 3 months ago

Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Aug 5, 2025, 7:00 AM EDT - 3 months ago

Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis

Jun 17, 2025, 8:00 AM EDT - 5 months ago

Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer

Jun 4, 2025, 8:00 AM EDT - 5 months ago

Elicio Therapeutics Secures $10 Million in Financing

May 13, 2025, 4:05 PM EDT - 6 months ago

Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Apr 16, 2025, 4:05 PM EDT - 7 months ago

Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires

Mar 31, 2025, 7:00 AM EDT - 8 months ago

Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates

Mar 24, 2025, 7:00 AM EDT - 8 months ago

Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer

Jan 31, 2025, 12:22 PM EST - 10 months ago

Elicio: Lymph Node Binding With ELI-002 Could Lead To Substantial 1st Half 2025 Data

Jan 22, 2025, 7:30 AM EST - 10 months ago

Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy

Dec 12, 2024, 7:00 AM EST - 1 year ago

Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024

Nov 13, 2024, 4:05 PM EST - 1 year ago

Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Nov 7, 2024, 4:05 PM EST - 1 year ago

Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting

Oct 31, 2024, 8:30 AM EDT - 1 year ago

Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit

Sep 13, 2024, 8:30 AM EDT - 1 year ago

Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines

Aug 28, 2024, 8:00 AM EDT - 1 year ago

Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 13, 2024, 4:30 PM EDT - 1 year ago

Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Jun 27, 2024, 4:05 PM EDT - 1 year ago

Elicio Therapeutics Announces Proposed Public Offering

Jun 27, 2024, 4:01 PM EDT - 1 year ago

Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P

May 23, 2024, 5:30 PM EDT - 1 year ago

Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting

May 15, 2024, 4:30 PM EDT - 1 year ago

Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Apr 25, 2024, 8:30 AM EDT - 1 year ago

Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting

Apr 5, 2024, 4:30 PM EDT - 1 year ago

Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting

Mar 29, 2024, 8:30 AM EDT - 1 year ago

Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates

Mar 18, 2024, 8:00 AM EDT - 1 year ago

Elicio Therapeutics Announces $6.0 Million Private Placement Financing

Mar 6, 2024, 8:30 AM EST - 1 year ago

Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting

Feb 5, 2024, 8:30 AM EST - 1 year ago

Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 25, 2024, 9:00 AM EST - 1 year ago

Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors

Jan 17, 2024, 8:30 AM EST - 1 year ago

Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium

Jan 16, 2024, 8:30 AM EST - 1 year ago

Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference

Jan 11, 2024, 8:30 AM EST - 2 years ago

Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study

Jan 9, 2024, 6:00 AM EST - 2 years ago

Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic's AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002

Dec 22, 2023, 9:00 AM EST - 2 years ago

Elicio Therapeutics Announces $7.0 Million Private Placement Financing

Dec 4, 2023, 8:00 AM EST - 2 years ago

Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference

Nov 9, 2023, 4:30 PM EST - 2 years ago

Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Nov 3, 2023, 4:30 PM EDT - 2 years ago

Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting

Oct 11, 2023, 8:00 AM EDT - 2 years ago

Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC 2023) Annual Meeting

Sep 27, 2023, 5:30 PM EDT - 2 years ago

Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer

Sep 7, 2023, 8:00 AM EDT - 2 years ago

Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines

Sep 6, 2023, 8:00 AM EDT - 2 years ago

Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic Cancer

Woooehoo Nov. 14 at 5:00 PM

0 · Reply

GA09 Nov. 14 at 1:05 PM

$ELTX Another delay in release of the data. It was supposed to be Q1 2025, then Q3 2025, then Q4 2025 and now 1st half of 2026. They keep changing the goal posts. Does this make sense?

1 · Reply

justiceforb_85 Nov. 14 at 3:35 AM

$ELTX think it's likely good news of delay of DFS to H1 '26. Science behind ELI-002 7P is strong. Financials of company are a bit shaky. Would be nice to see a possible buyout before data read-out.

2 · Reply

GA09 Nov. 11 at 7:45 PM

1 · Reply

DARKP00L Nov. 7 at 2:24 PM

0 · Reply

Woooehoo Nov. 6 at 3:00 PM

1 · Reply

Cbra Nov. 4 at 12:04 PM

$ELTX agreed, it’s as if nobody knows what’s going with this company, in this sector!

2 · Reply

humdime Nov. 4 at 11:10 AM

0 · Reply

Olatz Nov. 3 at 4:28 PM

$ELTX https://elicio.com/press_releases/elicio-therapeutics-to-present-clinical-and-preclinical-data-at-the-sitc-2025-annual-meeting/

0 · Reply

justiceforb_85 Oct. 27 at 7:43 PM

$ELTX excellent data update. Look forward to DFS data.

1 · Reply

SweetHome Oct. 27 at 1:27 PM

$ELTX https://www.globenewswire.com/news-release/2025/10/27/3174537/0/en/Elicio-Therapeutics-Reports-Robust-T-cell-Responses-Across-Diverse-HLA-backgrounds-in-Ongoing-Phase-2-AMPLIFY-7P-Trial.html

0 · Reply

Stock_Catcher Oct. 27 at 1:26 PM

$ELTX Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial

0 · Reply

Woooehoo Oct. 22 at 11:03 AM

$ELTX I see it as unlikely this doesn’t go decently higher or decently lower with data in q4

3 · Reply

ChaseDeluca Oct. 19 at 8:33 PM

Don’t sleep on VRME while many tech names trade on hype, this one trades on value + technical setup. Golden cross brewing on the daily, 10‑day action above $1 reflecting compliance improvement, and it’s still under the radar. This combination rarely stays hidden for long. $PSNY $ELTX $XELA $SLNO

0 · Reply

justiceforb_85 Oct. 12 at 2:22 AM

$ELTX we've received a possible hint that DFS wil be outstanding in the P2. Median mKRAS-specific T cell response ~44 when prior studies showed clinical efficacy around 9.17. I am very hopeful this translates into clinically meaningful outcomes. https://elicio.com/press_releases/elicio-therapeutics-reports-eli-002-7p-achieved-robust-mkras-specific-t-cell-responses-in-99-of-evaluable-patients-in-ongoing-phase-2-amplify-7p-trial/

0 · Reply

COYIinnewyork Oct. 9 at 6:43 PM

$ELTX I've only been holding a few thousand shares. I'm holding it amongst others, but I've always wondered with this in particular why MRK, BMY, or PFE don't swoop it up to fill their immuno-oncology pipelines. Do you think they are waiting on the specific data like everyone else? Would ELTX sell to one of them on positive data or would partnering be the way to go?

1 · Reply

outlawinvestor1 Oct. 3 at 4:38 PM

$ERAS #KRAS landscape. SA doesn't update mc/ev in real-time - ERAS mc is now ~$720 million, cash is ~$350 million. @Night_Owl_Biotech $RVMD $VSTM $ELTX $ARVN

0 · Reply

justiceforb_85 Sep. 29 at 7:12 PM

$ELTX this is excellent news and means more patients would potentially qualify for ELI-002 7P. https://elicio.com/press_releases/elicio-therapeutics-announces-investigator-initiated-phase-1-trial-to-be-conducted-by-memorial-sloan-kettering-cancer-center-and-funded-by-the-lustgarten-foundation-for-neoadjuvant-eli-002-7p-in-pancr/

0 · Reply

LawrenceLay406 Sep. 21 at 10:52 AM

$ELTX Biotech with novel approach. Pre-revenue volatility. Chart shows high risk/reward. Avoid.

0 · Reply

Woooehoo Sep. 18 at 12:17 PM

$ELTX if p2 is anything like p1 should show solid efficacy of T cell response is even better

2 · Reply

justiceforb_85 Sep. 17 at 4:59 PM

$ELTX looking forward to P2 data later this year. Wonder if they would qualify for accelerated approval pending P3 completion.

1 · Reply

PMMstocks Sep. 17 at 1:52 PM

$ELTX https://elicio.com/press_releases/elicio-therapeutics-reports-eli-002-7p-achieved-robust-mkras-specific-t-cell-responses-in-99-of-evaluable-patients-in-ongoing-phase-2-amplify-7p-trial/

0 · Reply

Market Cap	145.57M
Revenue (ttm)	0.00
Net Income (ttm)	-51.90M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	5.10

Volume	130,700
Avg Vol	89,262
Day's Range	N/A - N/A
Shares Out	16.34M
Stochastic %K	31%
Beta	1.18
Analysts	Strong Sell
Price Target	$15.50